Old website version
Рус Eng
  • About center
    • General Information
    • History
    • Areas of Research
    • Departments and laboratories
    • Management of the Center
    • Microbiology Council
    • Dissertations Committees
    • Ethics Committee
    • Russian Ministry of Health and WHO Centers
    • Institute of Virology
    • «Medgamal» Branch
    • Electronic Library
  • Research
    • Vaccine against COVID-19
    • Ebola
    • MERS
    • Influenza vaccine
    • Ftortiazinon
    • Pertussis Vaccine
  • Education
    • Department of Infectious Diseases and Virology
    • Postgraduate Studies
  • Newsroom
    • Main news
    • News from the Academic Council
    • News from Dissertation Committees
    • News from the Microbiology Academic Committee
    • News from departments and laboratories
    • Educational news
    • Professional scientific potential
    • EBOLA vaccine
    • Media about us
    • News of the «Medgamal» Branch
  • Contacts
  • About center
    • General Information
    • History
    • Areas of Research
    • Departments and laboratories
    • Management of the Center
    • Microbiology Council
    • Dissertations Committees
    • Ethics Committee
    • Russian Ministry of Health and WHO Centers
    • Institute of Virology
    • «Medgamal» Branch
    • Electronic Library
  • Research
    • Vaccine against COVID-19
    • Ebola
    • MERS
    • Influenza vaccine
    • Ftortiazinon
    • Pertussis Vaccine
  • Education
    • Department of Infectious Diseases and Virology
    • Postgraduate Studies
  • Newsroom
    • Main news
    • News from the Academic Council
    • News from Dissertation Committees
    • News from the Microbiology Academic Committee
    • News from departments and laboratories
    • Educational news
    • Professional scientific potential
    • EBOLA vaccine
    • Media about us
    • News of the «Medgamal» Branch
  • Contacts
  • Vaccine against COVID-19
  • Ebola
  • MERS
  • Influenza vaccine
  • Ftortiazinon
  • Pertussis Vaccine

Influenza vaccine

Clinical trial:

A Double-blind Randomized Placebo-controlled Study Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac

The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac

Scientific publications:

Tutykhina I, Esmagambetov I, Bagaev A, et al. Vaccination potential of B and T epitope-enriched NP and M2 against Influenza A viruses from different clades and hosts. Published 2018 Jan 29.

Tutykhina IL, Logunov DY, Shcherbinin DN, et al. Development of adenoviral vector-based mucosal vaccine against influenza. 2011. J Mol Med (Berl).

International patents:

Patent WO2013129961A1 Recombinant trivalent vaccine against human influenza.

CONTACTS
18 Gamaleya St., Moscow, Russia,
123098
Tel.: +7 (499) 193-30-01
Fax: +7 (499) 193-61-83
E-mail: info@gamaleya.org
About center
General Information History Areas of Research Departments and laboratories Management of the Center Microbiology Council Dissertations Committees Ethics Committee Russian Ministry of Health and WHO Centers Institute of Virology «Medgamal» Branch Electronic Library
Research
Vaccine against COVID-19 Ebola MERS Influenza vaccine Ftortiazinon Pertussis Vaccine
Education
Department of Infectious Diseases and Virology Postgraduate Studies
Newsroom
Main news News from the Academic Council News from Dissertation Committees News from the Microbiology Academic Committee News from departments and laboratories Educational news Professional scientific potential EBOLA vaccine Media about us News of the «Medgamal» Branch
CONTACTS
18 Gamaleya St., Moscow, Russia, 123098
Tel.: +7 (499) 193-30-01
Fax: +7 (499) 193-61-83
E-mail: info@gamaleya.org
Contacts page
All rights reserved. 2023 Old website version